Latest Cancer immunoprevention Stories
The difference between an immune response that kills cancer cells and one that conversely stimulates tumor growth can be as narrow as a "double-edged sword," report researchers at the University of California, San Diego School of Medicine in the April 7, 2014 online issue of the Proceedings of the National Academy of Sciences.
New VPs of R&D and Clinical Development add extensive pharmaceutical and biotech immunotherapy product development experience BLUE BELL, Pa., Feb.
A novel drug developed by Gilead Sciences and tested in an animal model at the Texas Biomedical Research Institute in San Antonio suppresses hepatitis B virus infection by stimulating the immune system and inducing loss of infected cells.
ROCKVILLE, Md., June 2 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), today announced the publication of preclinical results for its clinical-stage Aurora A/angiogenic kinase inhibitor, ENMD-2076, in human colorectal cancer xenograft models.
NEW ORLEANS, Dec. 8 /PRNewswire-FirstCall/ -- Micromet, Inc.
Older cancer sufferers need treatments tailored to their aging immune systems.
Immune responses are capable of killing tumors before they can be directed toward normal body tissue, according to new scientific findings published in Cancer Research, a journal of the American Association for Cancer Research.
Hepatitis B virus (HBV) infection is a dynamic process with variable biochemical, virological and histological profiles at different stages of the infection, depending on host and viral factors.
- totally perplexed and mixed up.